- Optimi Health (OPTI) will manufacture and supply MDMA for the program set to take place later this year, pending clinical trial approval
- The clinical trial will give practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training
- Optimi CEO Bill Ciprick says this latest supply partnership shows the dedication the company is implementing to support therapists
- Optimi Health is an end-to-end Canadian-based drug researcher and formulator
- Optimi Health (OPTI) is down 2.33 per cent, trading at C$0.21 at 11:09 am ET
Optimi Health (CSE:OPTI) will produce and supply psychedelic substances such as GMP-grade 3,4-Methylenedioxymethamphetamine (MDMA) and natural psilocybin.
The clinical trial will give practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training.
The clinical trial application was submitted and if approved by Health Canada, it will enable practitioners interested in MDMA-assisted therapy the ability to experience and observe MDMA sessions, furthering their understanding of psychedelic-assisted therapies.
Numinus founder and CEO Payton Nyquvest, added: “We are thrilled to announce this unique partnership with Optimi that opens the doors to a groundbreaking opportunity for psychedelic therapists worldwide.”
Optimi CEO Bill Ciprick said this latest supply partnership shows the dedication the company is implementing to support therapists and be a preferred supplier of MDMA.
“Optimi is committed to supporting Numinus and MAPS as they prepare to meet this immediate need for therapist and practitioner training,” Ciprick said. “Therapists provided experiential training within the parameters of this partnership will be able to provide a greater standard of care to patients undergoing these treatments.”
“This collaboration represents our unwavering commitment to expanding the frontiers of mental health, providing a safe and guided path towards profound healing and personal growth,” Nyquvest said.
Optimi will answer questions during a live webinar after the MAPS Psychedelic Science 2023 conference.
Optimi Health is an end-to-end Canadian-based drug researcher and formulator.
Optimi Health (OPTI) is down 2.33 per cent, trading at C$0.21 at 11:09 am ET.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
